PMID- 32673826
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 147
DP  - 2020 Sep
TI  - Enhanced prognostic stratification of neoadjuvant treated lung squamous cell 
      carcinoma by computationally-guided tumor regression scoring.
PG  - 49-55
LID - S0169-5002(20)30514-6 [pii]
LID - 10.1016/j.lungcan.2020.07.003 [doi]
AB  - INTRODUCTION: The amount of residual tumor burden after neoadjuvant chemotherapy 
      is an important prognosticator, but for non-small cell lung carcinoma (NSCLC), no 
      official regression scoring system is yet established. Computationally derived 
      histological regression scores could provide unbiased and quantitative readouts 
      to complement the clinical assessment of treatment response. METHODS: 
      Histopathologic tumor regression was microscopically assessed on whole cases in a 
      neoadjuvant chemotherapy-treated cohort (NAC, n = 55 patients) of lung squamous 
      cell carcinomas (LSCC). For each patient, the slide showing the least pathologic 
      regression was selected for subsequent computational analysis and histological 
      features were quantified: percentage of vital tumor cells (cTu.Percentage), total 
      surface covered by vital tumor cells (cTu.Area), area of the largest vital tumor 
      fragment (cTu.Size.max), and total number of vital tumor fragments 
      (cTu.Fragments). A chemo-naive LSCC cohort (CN, n = 104) was used for reference. 
      For 23 of the 55 patients [(18)F]-Fluorodeoxyglucose (FDG) PET/CT measurements of 
      maximum standard uptake value (SUV(max)), background subtracted lesion activity 
      (BSL) and background subtracted volume (BSV) were correlated with pathologic 
      regression. Survival analysis was carried out using Cox regression and receiver 
      operating characteristic (ROC) curve analysis using a 3-years cutoff. RESULTS: 
      All computational regression parameters significantly correlated with relative 
      changes of BSV FDG PET/CT values after neoadjuvant chemotherapy. ROC curve 
      analysis of histological parameters of NAC patients showed that cTu.Percentage 
      was the most accurate prognosticator of overall survival (ROC curve AUC = 0.77, 
      p-value = 0.001, Cox regression HR = 3.6, p = 0.001, variable cutoff < = 30 %). 
      CONCLUSIONS: This study demonstrates the prognostic relevance of computer-derived 
      histopathologic scores. Additionally, the analysis carried out on slides 
      displaying the least pathologic regression correlated with overall pathologic 
      response and PET/CT values. This might improve the objective histopathologic 
      assessment of tumor response in neoadjuvant setting.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Casanova, Ruben
AU  - Casanova R
AD  - Institute of Pathology and Molecular Pathology, University Hospital Zurich, 
      Switzerland. Electronic address: ruben.casanova@uzh.ch.
FAU - Leblond, Anne-Laure
AU  - Leblond AL
AD  - Institute of Pathology and Molecular Pathology, University Hospital Zurich, 
      Switzerland.
FAU - Wu, Chengguang
AU  - Wu C
AD  - Institute of Pathology and Molecular Pathology, University Hospital Zurich, 
      Switzerland.
FAU - Haberecker, Martina
AU  - Haberecker M
AD  - Institute of Pathology and Molecular Pathology, University Hospital Zurich, 
      Switzerland.
FAU - Burger, Irene A
AU  - Burger IA
AD  - Department of Nuclear Medicine, University Hospital Zurich, Switzerland.
FAU - Soltermann, Alex
AU  - Soltermann A
AD  - ADMED Pathology, Neuchatel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200703
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - *Carcinoma, Squamous Cell/drug therapy
MH  - Fluorodeoxyglucose F18
MH  - Humans
MH  - Lung
MH  - *Lung Neoplasms/diagnosis/drug therapy
MH  - Neoadjuvant Therapy
MH  - Positron Emission Tomography Computed Tomography
MH  - Positron-Emission Tomography
MH  - Prognosis
MH  - Radiopharmaceuticals
OTO - NOTNLM
OT  - Computational pathology
OT  - Lung
OT  - Neoadjuvant chemotherapy
OT  - Prognosis
OT  - Squamous cell carcinoma
EDAT- 2020/07/17 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/04/15 00:00 [received]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/07/17 06:00 [entrez]
AID - S0169-5002(20)30514-6 [pii]
AID - 10.1016/j.lungcan.2020.07.003 [doi]
PST - ppublish
SO  - Lung Cancer. 2020 Sep;147:49-55. doi: 10.1016/j.lungcan.2020.07.003. Epub 2020 
      Jul 3.